|
1
|
Balmer A, Zografos L and Munier F:
Diagnosis and current management of retinoblastoma. Oncogene.
25:5341–5349. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alonso J, Garcia-Miguel P, Abelairas J,
Mendiola M and Pestaña A: A microsatellite fluorescent method for
linkage analysis in familial retinoblastoma and deletion detection
at the RB1 locus in retinoblastoma and osteosarcoma. Diagn Mol
Pathol. 10:9–14. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dimaras H, Kimani K, Dimba EA, Gronsdahl
P, White A, Chan HS and Gallie BL: Retinoblastoma. Lancet.
379:1436–1446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kleinerman RA, Schonfeld SJ and Tucker MA:
Sarcomas in hereditary retinoblastoma. Clin Sarcoma Res. 2:152012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marees T, Moll AC, Imhof SM, de Boer MR,
Ringens PJ and van Leeuwen FE: Risk of second malignancies in
survivors of retinoblastoma: More than 40 years of follow-up. J
Natl Cancer Inst. 100:1771–1779. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moll AC, Imhof SM, Bouter LM and Tan KE:
Second primary tumors in patients with retinoblastoma. A review of
the literature. Ophthalmic Genet. 18:27–34. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Beta M, Venkatesan N, Vasudevan M,
Vetrivel U, Khetan V and Krishnakumar S: Identification and
insilico analysis of retinoblastoma serum microRNA profile and gene
targets towards prediction of novel serum biomarkers. Bioinform
Biol Insights. 7:21–34. 2013.PubMed/NCBI
|
|
8
|
Wang J, Wang X, Wu G, Hou D and Hu Q:
MiR-365b-3p, down-regulated in retinoblastoma, regulates cell cycle
progression and apoptosis of human retinoblastoma cells by
targeting PAX6. FEBS Lett. 587:1779–1786. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Friedman DL, Himelstein B, Shields CL,
Shields JA, Needle M, Miller D, Bunin GR and Meadows AT:
Chemoreduction and local ophthalmic therapy for intraocular
retinoblastoma. J Clin Oncol. 18:12–17. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shields CL and Shields JA: Diagnosis and
management of retinoblastoma. Cancer Control. 11:317–327.
2004.PubMed/NCBI
|
|
11
|
Xu X, Jia R, Zhou Y, Song X, Wang J, Qian
G, Ge S and Fan X: Microarray-based analysis: Identification of
hypoxia-regulated microRNAs in retinoblastoma cells. Int J Oncol.
38:1385–1393. 2011.PubMed/NCBI
|
|
12
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thieu W, Tilki D, White RW deVere and
Evans CP: The role of microRNA in castration-resistant prostate
cancer. Urol Oncol. 32:517–523. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reardon DA, Rich JN, Friedman HS and
Bigner DD: Recent advances in the treatment of malignant
astrocytoma. J Clin Oncol. 24:1253–1265. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer. 96
Suppl:R40–R44. 2007.PubMed/NCBI
|
|
16
|
Calin GA, Ferracin M, Cimmino A, Di Leva
G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et
al: A MicroRNA signature associated with prognosis and progression
in chronic lymphocytic leukemia. N Engl J Med. 353:1793–1801. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Montoya V, Fan H, Bryar PJ, Weinstein JL,
Mets MB, Feng G, Martin J, Martin A, Jiang H and Laurie NA: Novel
miRNA-31 and miRNA-200a-mediated regulation of retinoblastoma
proliferation. PLoS One. 10:e01383662015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu X, Zeng Y, Wu S, Zhong J, Wang Y and Xu
J: MiR-204, down-regulated in retinoblastoma, regulates
proliferation and invasion of human retinoblastoma cells by
targeting CyclinD2 and MMP-9. FEBS Lett. 589:645–650. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shen F, Mo MH, Chen L, An S, Tan X, Fu Y,
Rezaei K, Wang Z, Zhang L and Fu SW: MicroRNA-21 Down-regulates Rb1
expression by targeting PDCD4 in retinoblastoma. J Cancer.
5:804–812. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Porkka KP, Pfeiffer MJ, Waltering KK,
Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression
profiling in prostate cancer. Cancer Res. 67:6130–6135. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun JY, Xiao WZ, Wang F, Wang YQ, Zhu YH,
Wu YF, Miao ZL and Lin YC: MicroRNA-320 inhibits cell proliferation
in glioma by targeting E2F1. Mol Med Rep. 12:2355–2359.
2015.PubMed/NCBI
|
|
22
|
Wan LY, Deng J, Xiang XJ, Zhang L, Yu F,
Chen J, Sun Z, Feng M and Xiong JP: miR-320 enhances the
sensitivity of human colon cancer cells to chemoradiotherapy in
vitro by targeting FOXM1. Biochem Biophys Res Commun. 457:125–132.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cheng C, Chen ZQ and Shi XT: MicroRNA-320
inhibits osteosarcoma cells proliferation by directly targeting
fatty acid synthase. Tumour Biol. 35:4177–4183. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lei Q, Shen F, Wu J, Zhang W, Wang J and
Zhang L: MiR-101, downregulated in retinoblastoma, functions as a
tumor suppressor in human retinoblastoma cells by targeting EZH2.
Oncol Rep. 32:261–269. 2014.PubMed/NCBI
|
|
26
|
Wu YY, Chen YL, Jao YC, Hsieh IS, Chang KC
and Hong TM: miR-320 regulates tumor angiogenesis driven by
vascular endothelial cells in oral cancer by silencing neuropilin
1. Angiogenesis. 17:247–260. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hsieh IS, Chang KC, Tsai YT, Ke JY, Lu PJ,
Lee KH, Yeh SD, Hong TM and Chen YL: MicroRNA-320 suppresses the
stem cell-like characteristics of prostate cancer cells by
downregulating the Wnt/beta-catenin signaling pathway.
Carcinogenesis. 34:530–538. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li M, Marin-Muller C, Bharadwaj U, Chow
KH, Yao Q and Chen C: MicroRNAs: Control and loss of control in
human physiology and disease. World J Surg. 33:667–684. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schaar DG, Medina DJ, Moore DF, Strair RK
and Ting Y: miR-320 targets transferrin receptor 1 (CD71) and
inhibits cell proliferation. Exp Hematol. 37:245–255. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chang WC and Hung JJ: Functional role of
post-translational modifications of Sp1 in tumorigenesis. J Biomed
Sci. 19:942012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Black AR, Black JD and Azizkhan-Clifford
J: Sp1 and kruppel-like factor family of transcription factors in
cell growth regulation and cancer. J Cell Physiol. 188:143–160.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li L, He S, Sun JM and Davie JR: Gene
regulation by Sp1 and Sp3. Biochem Cell Biol. 82:460–471. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mukhopadhyay D and Datta K: Multiple
regulatory pathways of vascular permeability factor/vascular
endothelial growth factor (VPF/VEGF) expression in tumors. Semin
Cancer Biol. 14:123–130. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann
E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, et al:
Bortezomib induces DNA hypomethylation and silenced gene
transcription by interfering with Sp1/NF-kappaB-dependent DNA
methyltransferase activity in acute myeloid leukemia. Blood.
111:2364–2373. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chadalapaka G, Jutooru I, Chintharlapalli
S, Papineni S, Smith R III, Li X and Safe S: Curcumin decreases
specificity protein expression in bladder cancer cells. Cancer Res.
68:5345–5354. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pathi SS, Jutooru I, Chadalapaka G,
Sreevalsan S, Anand S, Thatcher GR and Safe S: GT-094, a NO-NSAID,
inhibits colon cancer cell growth by activation of a reactive
oxygen species-microRNA-27a: ZBTB10-specificity protein pathway.
Mol Cancer Res. 9:195–202. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hsu TI, Wang MC, Chen SY, Huang ST, Yeh
YM, Su WC, Chang WC and Hung JJ: Betulinic acid decreases
specificity protein 1 (Sp1) level via increasing the sumoylation of
sp1 to inhibit lung cancer growth. Mol Pharmacol. 82:1115–1128.
2012. View Article : Google Scholar : PubMed/NCBI
|
